496 related articles for article (PubMed ID: 31314869)
1. Biological bases for a possible effect of cannabidiol in Parkinson's disease.
Ferreira-Junior NC; Campos AC; Guimarães FS; Del-Bel E; Zimmermann PMDR; Brum Junior L; Hallak JE; Crippa JA; Zuardi AW
Braz J Psychiatry; 2020 Apr; 42(2):218-224. PubMed ID: 31314869
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
[TBL] [Abstract][Full Text] [Related]
3. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
[TBL] [Abstract][Full Text] [Related]
4. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
Chagas MH; Zuardi AW; Tumas V; Pena-Pereira MA; Sobreira ET; Bergamaschi MM; dos Santos AC; Teixeira AL; Hallak JE; Crippa JA
J Psychopharmacol; 2014 Nov; 28(11):1088-98. PubMed ID: 25237116
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease.
Giuliano C; Francavilla M; Ongari G; Petese A; Ghezzi C; Rossini N; Blandini F; Cerri S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445626
[TBL] [Abstract][Full Text] [Related]
6. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
Cooray R; Gupta V; Suphioglu C
Mol Neurobiol; 2020 Nov; 57(11):4878-4890. PubMed ID: 32813239
[TBL] [Abstract][Full Text] [Related]
7. Potential role of cannabidiol in Parkinson's disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation.
Vallée A; Vallée JN; Lecarpentier Y
Aging (Albany NY); 2021 Apr; 13(7):10796-10813. PubMed ID: 33848261
[TBL] [Abstract][Full Text] [Related]
8. Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM; Mali S; Amin PD; Oliveira M
J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
[TBL] [Abstract][Full Text] [Related]
10. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
11. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.
Patricio F; Morales-Andrade AA; Patricio-Martínez A; Limón ID
Front Pharmacol; 2020; 11():595635. PubMed ID: 33384602
[TBL] [Abstract][Full Text] [Related]
12. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol for the treatment of psychosis in Parkinson's disease.
Zuardi AW; Crippa JA; Hallak JE; Pinto JP; Chagas MH; Rodrigues GG; Dursun SM; Tumas V
J Psychopharmacol; 2009 Nov; 23(8):979-83. PubMed ID: 18801821
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC; Fogaça MV; Sonego AB; Guimarães FS
Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
[TBL] [Abstract][Full Text] [Related]
15. Evidences for the Anti-panic Actions of Cannabidiol.
Soares VP; Campos AC
Curr Neuropharmacol; 2017; 15(2):291-299. PubMed ID: 27157263
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Zuardi AW
Braz J Psychiatry; 2008 Sep; 30(3):271-80. PubMed ID: 18833429
[TBL] [Abstract][Full Text] [Related]
17. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease.
Li H; Liu Y; Tian D; Tian L; Ju X; Qi L; Wang Y; Liang C
Eur J Med Chem; 2020 Apr; 192():112163. PubMed ID: 32109623
[TBL] [Abstract][Full Text] [Related]
18. The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.
Santos NA; Martins NM; Sisti FM; Fernandes LS; Ferreira RS; Queiroz RH; Santos AC
Toxicol In Vitro; 2015 Dec; 30(1 Pt B):231-40. PubMed ID: 26556726
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
[TBL] [Abstract][Full Text] [Related]
20. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
de Faria SM; de Morais Fabrício D; Tumas V; Castro PC; Ponti MA; Hallak JE; Zuardi AW; Crippa JAS; Chagas MHN
J Psychopharmacol; 2020 Feb; 34(2):189-196. PubMed ID: 31909680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
